title: [Management of febrile neutropenia in cancer patients].
abstract: The incidence of cancer is raising and the treatments are increasingly aggressive. Consequently, general practitioners, emergency departments, hematologists and oncologists are regularly facing a severe side-effect of cytotoxic therapy, febrile neutropenia (FN). FN is a serious complication of chemotherapy because it can be quickly fatal and causes a temporary or definitive cessation of treatment. In this article, we summarize the latest recommendations for the management of patients with FN under anti-cancer treatments.
authors.forename: P
authors.initials: P
authors.lastname: Freres
authors.forename: E
authors.initials: E
authors.lastname: Gonne
authors.forename: J
authors.initials: J
authors.lastname: Collignon
authors.forename: J B
authors.initials: JB
authors.lastname: Giot
authors.forename: C
authors.initials: C
authors.lastname: Gennigens
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000175:diagnosis / Q000628:therapy*; D016903:Drug Monitoring / Q000379:methods; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor